Emerging Biomarkers and Targeted Therapies Reshaping Clinical Management of Colorectal Cancer DOI Open Access

Tamer A. Addissouky

Cancer Research and Cellular Therapeutics, Journal Year: 2023, Volume and Issue: 8(2), P. 01 - 06

Published: March 20, 2023

Background: Colorectal cancer (CRC) is a leading cause of deaths worldwide. Key risk factors include lifestyle, diet, inflammation, and family history. Understanding molecular pathways underlying CRC initiation progression critical to guide prevention treatment. Purpose: This review summarizes recent advances in screening, therapy, future directions. Main body: New stool DNA panels blood-based assays offer non-invasive options for early detection, though require further validation. Immuno- targeted therapies matched tumor profiles have transformed metastatic Pembrolizumab elicits durable responses mismatch repair-deficient tumors, anti-EGFR antibodies cetuximab/panitumumab improve outcomes left-sided RAS/RAF wild-type CRC. Larotrectinib entrectinib are highly active NTRK fusion-positive Research focusing on new immunotherapies, leveraging the microbiome, combining multi-omics data enable precision medicine holds promise. Disparities across groups remain challenge. Conclusions: Recent therapeutic significantly improved survival patients. Advances diagnostics, next-generation sequencing, computational approaches will more sophisticated profiling tailored therapy selection. Realizing potential emerging immunotherapies integrating knowledge microbiome important frontiers.

Language: Английский

Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy DOI
Shaida Ouladan, Elias Orouji

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful hematologic malignancies, presents promising avenue for treating solid tumors, including CRC. This review explores potential CAR-T therapy by analyzing clinical trials highlighting prominent CRC-specific targets. We discuss challenges such as immunosuppressive microenvironment, tumor heterogeneity, physical barriers that limit efficacy. Emerging strategies, logic-gated dual-targeting cells, offer practical solutions to overcome these hurdles. Furthermore, we explore combination immune checkpoint inhibitors enhance T-cell persistence infiltration. As field continues evolve, therapies hold significant revolutionizing landscape

Language: Английский

Citations

3
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer DOI Open Access

Jennifer Haynes,

Prasath Manogaran

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1988 - 1988

Published: Feb. 25, 2025

Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide, with significant impact on public health. Current treatment options include surgery, chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy. Despite advancements in these therapeutic modalities, resistance remains challenge, often leading to failure, poor progression-free survival, recurrence. Mechanisms CRC are multifaceted, involving genetic mutations, epigenetic alterations, tumor heterogeneity, the microenvironment. Understanding mechanisms at molecular level crucial for identifying novel targets developing strategies overcome resistance. This review provides an overview diverse driving drug sporadic discusses currently under investigation counteract this Several promising being explored, including targeting transport, key signaling pathways, DNA damage response, cell death modifications, stem cells, The integration emerging approaches that target aims enhance efficacy current treatments improve patient outcomes.

Language: Английский

Citations

1
Multi-Drug Resistance and Breast Cancer Progression via Toll-Like Receptors (TLRs) Signaling DOI

Harikumar Pallathadka,

Abdulrahman Qais Khaleel,

Ahmed Hussein Zwamel

et al.

Cell Biochemistry and Biophysics, Journal Year: 2024, Volume and Issue: 82(4), P. 3015 - 3030

Published: Aug. 7, 2024

Language: Английский

Citations

4
Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective DOI Creative Commons

Vaishak Kaviyarasan,

Alakesh Das,

Dikshita Deka

et al.

International Journal of Colorectal Disease, Journal Year: 2024, Volume and Issue: 40(1)

Published: Dec. 28, 2024

Abstract Purpose Colorectal cancer (CRC) remains one of the leading causes cancer-related mortality worldwide. Metastatic colorectal (mCRC) continues to present significant challenges, particularly in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors. This narrative review aims provide recent developments immunotherapy for CRC treatment, focusing on its efficacy and challenges. Methods discussed various immunotherapeutic strategies including immune checkpoint inhibitors (ICIs) targeting PD-1 PD-L1, combination therapies involving ICIs other modalities, chimeric antigen receptor T-cell (CAR-T) cell therapy, vaccines. The role tumor microenvironment evasion mechanisms was also explored understand their impact effectiveness these therapies. Results provides a comprehensive update advancements CRC, highlighting potential approaches, inhibitors, therapies, CAR-T vaccination strategies. results MSI-H/dMMR tumors, which have improvements survival rates been observed. Furthermore, this addresses challenges faced treating pMMR/MSS resistant immunotherapy. Conclusion Immunotherapy plays treatment However, many remain, especially CRC. need further research into biomarker development, deeper understanding treatment.

Language: Английский

Citations

4
Single-cell analysis of colon cancer: Novel insight into drug resistance and immunotherapy DOI

Priyamvada Bhamidipati,

Sridhar V.N.S. Kocharlakota,

Vedavathi Katneni

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 105 - 112

Published: Jan. 1, 2025

Language: Английский

Citations

0
Recent advances in oncolytic virus combined immunotherapy in tumor treatment DOI Creative Commons
Xiaoli Zhou, Shunfeng Hu, Xin Wang

et al.

Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101599 - 101599

Published: March 1, 2025

Language: Английский

Citations

0
Identification of lncRNA associated with the SERPINE1 gene in colorectal cancer through TGF-β pathway DOI

Ghazale Habibzadeh,

Khatere Mokhtari,

Masoumeh Heshmati

et al.

Computers in Biology and Medicine, Journal Year: 2025, Volume and Issue: 190, P. 110037 - 110037

Published: March 19, 2025

Language: Английский

Citations

0
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota DOI
Ali Rahimi,

Zeinab Baghernejadan,

Ali Hazrati

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 186, P. 118014 - 118014

Published: March 31, 2025

Language: Английский

Citations

0
Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification DOI Creative Commons

Ningye Ma,

Jian Gao,

Xiaoao Pang

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 383, P. 113822 - 113822

Published: May 9, 2025

Language: Английский

Citations

0
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model DOI
Atefeh Yari, Seyed Younes Hosseini,

Sanaz Asiyabi

et al.

Immunotherapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 11

Published: May 12, 2025

The effectiveness of immunotherapy with tumor associated antigen vaccines can be enhanced by combining oncolytic viruses immune checkpoint inhibitors. This study evaluates the efficacy reovirus in combination an adenovector expressing carcinoembryonic (Ad-CEA) and a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor mouse model. Mice bearing CEA-expressing CT26 cells were immunized Ad-CEA along PD-1/PD-L1 inhibitor. Subsequently, three doses injected into tumors. Tumor size, histopathological examination, CD8 FOXP3 expression, cytotoxicity spleen T cell lymphocytes, secretion Interferon-γ (IFN-γ) necrosis factor- α (TNF-α) examined. triple therapy used this resulted lowest growth highest level cytotoxic immunity. Foxp3 levels microenvironment TNF-α decreased compared to other control groups. Additionally, group exhibited number mitotic figures amount tumor-infiltrating lymphocytes. significantly improves treatment efficacy. Furthermore, inhibiting interaction during vaccination also virotherapy enhances immunovirotherapy reducing immunosuppressive effects stimulating system, leading improved therapeutic outcomes.

Language: Английский

Citations

0